Trial Profile
Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF) Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose) in Healthy Female Subjects (an Open-label, Randomised, Single-dose, Three-period, Three-sequence Crossover Study at Two Different Dose Strengths)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Sep 2015
Price :
$35
*
At a glance
- Drugs BI 1060469 (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 23 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Aug 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 12 May 2015 New trial record